ClinicalTrials.gg
CompletedNCT01266161Updated Aug 15, 2018Results posted

Multiple Dose Dental Pain Study Of Ibuprofen Extended Release

A Phase 3 interventional study of Ibuprofen 600 mg ER and Placebo in Pain, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
41st of 86
106 · median 100
Started
2010
with 3 others
Phase 3
22 of 86
none open now
Registered
18th of 86
by date
Lead sponsor
8 of 86
Pfizer

Among the 86 studies testing ibuprofen in Pain, this one is the 41st largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 18th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The study hypothesis is that single and multiple doses of ibuprofen 600 mg ER caplets provide analgesic efficacy superior to placebo over 12-hour dosing intervals.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • dental pain
  • multiple dose
  • ibuprofen
  • third molar extraction
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 16 to 40 years of age
  • Subjects who undergo surgical removal of at least two third molars
  • One of which must be a partial or full bony mandibular impaction
  • Subjects must have at least moderate baseline pain (a score of 2 on the categorical pain severity rating scale) confirmed by a score of at least 50 mm on the 100-mm visual analog scale-pain severity rating scale (VAS-PSR)

Exclusion criteria

Exclusion Criteria:

  • Acute localized dental infection at the time of surgery that could confound the post-surgical evaluation
  • Presence or history of any significant organ disease
  • Use of prescription or OTC first generation antihistamines
  • Females who are pregnant, lactating or of and not using a medically approved method to prevent pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Ibuprofen 600 mg extended release

    Drug: Ibuprofen 600 mg ER

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • One 600 mg caplet dosed at 0, 12, 24 and 36 hours

  • DrugPlacebo

    One placebo caplet dosed at times 0, 12, 24 and 36 hours

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)

    SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0 equals \[=\] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.

    Time frame: Baseline to 12 hours

  2. Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose

    SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.

    Time frame: 8 to 12 hours

Secondary outcomes

  1. Time-weighted Sum of Pain Intensity Difference (SPID) Scores

    SPID is a derived endpoint from PID scores. For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.

    Time frame: 0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours

  2. Time to First Dose of Rescue Medication After First Dose of Study Drug

    During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.

    Time frame: Baseline to 12 hours

  3. Percentage of Participants Taking Rescue Medication

    Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.

    Time frame: Baseline to 48 hours

  4. Pain Relief (PR) Scores

    A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: "How much relief do you have from your starting pain?" Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.

    Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours

  5. Pain Intensity Difference (PID) Scores

    For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).

    Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours

  6. Pain Relief Combined With Pain Intensity (PRID) Scores

    PRID score=PR plus PID. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.

    Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours

  7. Time-weighted Sum of Pain Relief Scores (TOTPAR)

    TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).

    Time frame: 0-12 hours, 8-12 hours

  8. Number of Doses of Rescue Medication Used

    Time frame: 0-12, 12-24, 24-36, 36-48, 0-48 hours

  9. Time to Confirmed First Perceptible Relief

    The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.

    Time frame: Baseline to 12 hours

  10. Time to Meaningful Relief

    Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.

    Time frame: Baseline to 12 hours

  11. Participant Global Evaluation Score

    Participants responded, on a 6-point categorical scale, to the following question: "How would you rate this medication as a pain-reliever?" Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.

    Time frame: 24 and 48 hours

07

Results

Posted Aug 15, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboIbuprofen
Started5254
Completed4853
Not completed41
Withdrew: Ineligible10
Withdrew: Lack of efficacy01
Withdrew: Vomited within 4 hours of dosing30

Outcome measures

PrimaryTime-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)

SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0 equals \[=\] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.

Time frame:
Baseline to 12 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)
units on a scalePlaceboIbuprofen
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)18.2 ± 20.041.5 ± 21.0
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from analysis of variance (ANOVA) model, with treatment, baseline PSR, gender terms. To protect type I error at 5% significance, 2 primary parameters tested sequentially: SPRID 8-12 not declared significant unless SPRID 0-12 was significant.) · Mean difference (final values): 23.76 · 95% CI 16.45 to 31.07
PrimarySum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose

SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.

Time frame:
8 to 12 hours
Reported as:
Mean · units on a scale
Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose
units on a scalePlaceboIbuprofen
Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose10.3 ± 12.018.4 ± 12.1
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model, with treatment, baseline PSR, and gender terms. To protect type I error at 5% significance, 2 primary parameters tested sequentially: SPRID 8-12 not declared significant unless SPRID 0-12 was significant.) · Mean difference (final values): 8.42 · 95% CI 4.13 to 12.71
SecondaryTime-weighted Sum of Pain Intensity Difference (SPID) Scores

SPID is a derived endpoint from PID scores. For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.

Time frame:
0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Intensity Difference (SPID) Scores
units on a scalePlaceboIbuprofen
SPID 0-124.1 ± 9.612.8 ± 9.5
SPID 8-122.5 ± 5.45.5 ± 5.2
SPID 12-2412.5 ± 12.518.7 ± 11.7
SPID 20-248.8 ± 7.510.7 ± 7.3
SPID 0-2415.5 ± 19.329.9 ± 18.8
SPID 24-3616.2 ± 15.221.6 ± 13.9
SPID 32-367.0 ± 7.810.2 ± 7.4
SPID 36-4817.4 ± 14.223.0 ± 13.8
SPID 44-4810.5 ± 7.712.7 ± 7.3
SPID 24-4830.5 ± 25.240.7 ± 23.9
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 8.95 · 95% CI 5.94 to 11.95
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 3.15 · 95% CI 1.45 to 4.85
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 6.56 · 95% CI 2.84 to 10.27
  • Placebo vs Ibuprofen · ANOVA · p = 0.091 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 2.02 · 95% CI -0.33 to 4.37
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 14.95 · 95% CI 9.12 to 20.79
  • Placebo vs Ibuprofen · ANOVA · p = 0.010 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 5.87 · 95% CI 1.42 to 10.33
  • Placebo vs Ibuprofen · ANOVA · p = 0.004 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 3.48 · 95% CI 1.13 to 5.83
  • Placebo vs Ibuprofen · ANOVA · p = 0.006 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 6.09 · 95% CI 1.82 to 10.36
  • Placebo vs Ibuprofen · ANOVA · p = 0.042 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 2.41 · 95% CI 0.09 to 4.73
  • Placebo vs Ibuprofen · ANOVA · p = 0.004 (p-Value from ANOVA model with treatment, baseline PSR, and gender terms.) · Least-squares means: 10.97 · 95% CI 3.49 to 18.45
SecondaryTime to First Dose of Rescue Medication After First Dose of Study Drug

During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.

Time frame:
Baseline to 12 hours
Reported as:
Median · hours
Time to First Dose of Rescue Medication After First Dose of Study Drug
hoursPlaceboIbuprofen
Time to First Dose of Rescue Medication After First Dose of Study Drug1.6 (1.4 to 2.2)NA (NA to NA)
Statistical analysis
  • Placebo vs Ibuprofen · proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.18 · 95% CI 0.10 to 0.34
SecondaryPercentage of Participants Taking Rescue Medication

Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.

Time frame:
Baseline to 48 hours
Reported as:
Number · percentage of participants
Percentage of Participants Taking Rescue Medication
percentage of participantsPlaceboIbuprofen
First dosing interval (0 to 12 hours)76.929.6
Second dosing interval (12 to 24 hours)30.85.6
Third dosing interval (24 to 36 hours)32.79.3
Fourth dosing interval (36 to 48 hours)19.25.6
Overall during the study (0 to 48 hours)78.831.5
Statistical analysis
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Values from the Cochran-Mantel-Haenszel (CMH) test, controlling for baseline PSR and gender.) · Treatment difference: -48.01 · 95% CI -64.46 to -31.56
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Values from the CMH test, controlling for baseline PSR and gender.) · Treatment difference: -25.53 · 95% CI -39.78 to -11.28
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = 0.002 (p-Values from the CMH test, controlling for baseline PSR and gender.) · Treatment difference: -24.05 · 95% CI -38.93 to -9.18
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = 0.035 (p-Values from the CMH test, controlling for baseline PSR and gender.) · Treatment difference: -13.60 · 95% CI -26.41 to -0.79
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Values from the CMH test, controlling for baseline PSR and gender.) · Treatment difference: -48.01 · 95% CI -64.42 to -31.60
  • Placebo vs Ibuprofen · Andersen-Gill (AG) · p = 0.011 · Cox proportional hazard models: 0.086 · 95% CI 0.01 to 0.57
SecondaryPain Relief (PR) Scores

A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: "How much relief do you have from your starting pain?" Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.

Time frame:
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
Reported as:
Mean · units on a scale
Pain Relief (PR) Scores
units on a scalePlaceboIbuprofen
0.5 hours0.4 ± 0.71.3 ± 1.1
1 hour0.7 ± 1.02.2 ± 1.2
1.5 hours0.6 ± 1.02.6 ± 1.3
2 hours0.5 ± 1.02.8 ± 1.2
4 hours0.7 ± 1.32.9 ± 1.3
6 hours1.9 ± 1.32.8 ± 1.1
8 hours1.4 ± 1.32.4 ± 1.3
10 hours1.0 ± 1.32.1 ± 1.4
12 hours1.5 ± 1.51.9 ± 1.3
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.84 · 95% CI 0.50 to 1.19
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.53 · 95% CI 1.11 to 1.94
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 2.00 · 95% CI 1.56 to 2.44
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 2.29 · 95% CI 1.86 to 2.73
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 2.18 · 95% CI 1.69 to 2.68
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.92 · 95% CI 0.46 to 1.38Treatment difference (ibuprofen minus placebo) and corresponding 95% CI were calculated based on least-squares means from the ANOVA model.
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.04 · 95% CI 0.54 to 1.54
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.10 · 95% CI 0.59 to 1.60
  • Placebo vs Ibuprofen · ANOVA · p = 0.052 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.50 · 95% CI -0.00 to 1.01
SecondaryPain Intensity Difference (PID) Scores

For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).

Time frame:
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours
Reported as:
Mean · units on a scale
Pain Intensity Difference (PID) Scores
units on a scalePlaceboIbuprofen
0.5 hours0.1 ± 0.60.5 ± 0.7
1 hour0.1 ± 0.81.0 ± 0.9
1.5 hours0.0 ± 0.91.2 ± 0.9
2 hours-0.0 ± 0.81.4 ± 1.0
4 hours0.1 ± 1.01.4 ± 1.0
6 hours0.7 ± 1.01.3 ± 0.9
8 hours0.4 ± 0.91.0 ± 1.0
10 hours0.3 ± 0.90.9 ± 0.9
12 hours0.5 ± 1.20.8 ± 0.9
16 hours0.7 ± 0.91.6 ± 0.9
20 hours1.0 ± 1.01.4 ± 0.9
24 hours1.2 ± 1.01.2 ± 0.9
28 hours1.1 ± 1.11.6 ± 1.0
32 hours1.0 ± 1.01.6 ± 1.0
36 hours0.8 ± 1.01.0 ± 1.0
40 hours0.9 ± 1.01.6 ± 0.9
44 hours1.3 ± 1.01.6 ± 0.9
48 hours1.4 ± 1.01.6 ± 1.0
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.37 · 95% CI 0.16 to 0.59
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 0.90 · 95% CI 0.63 to 1.18
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 1.22 · 95% CI 0.91 to 1.52
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 1.40 · 95% CI 1.10 to 1.71
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 1.32 · 95% CI 0.97 to 1.67
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 0.61 · 95% CI 0.30 to 0.91
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 0.64 · 95% CI 0.31 to 0.97
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 0.66 · 95% CI 0.36 to 0.97
  • Placebo vs Ibuprofen · ANOVA · p = 0.089 (p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 0.27 · 95% CI -0.04 to 0.59
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (Ibuprofen versus placebo at 0.5 hours.) · Least squares means: 1.00 · 95% CI 0.70 to 1.29
  • Placebo vs Ibuprofen · ANOVA · p = 0.004 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.47 · 95% CI 0.15 to 0.78
  • Placebo vs Ibuprofen · ANOVA · p = 0.821 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.04 · 95% CI -0.28 to 0.35
  • Placebo vs Ibuprofen · ANOVA · p = 0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.56 · 95% CI 0.23 to 0.90
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.62 · 95% CI 0.30 to 0.94
  • Placebo vs Ibuprofen · ANOVA · p = 0.127 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.25 · 95% CI -0.07 to 0.57
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.67 · 95% CI 0.35 to 1.00
  • Placebo vs Ibuprofen · ANOVA · p = 0.036 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.34 · 95% CI 0.02 to 0.67
  • Placebo vs Ibuprofen · ANOVA · p = 0.091 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.26 · 95% CI -0.04 to 0.56
SecondaryPain Relief Combined With Pain Intensity (PRID) Scores

PRID score=PR plus PID. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.

Time frame:
0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
Reported as:
Mean · units on a scale
Pain Relief Combined With Pain Intensity (PRID) Scores
units on a scalePlaceboIbuprofen
0.5 hours0.6 ± 1.11.8 ± 1.6
1 hour0.8 ± 1.73.2 ± 2.0
1.5 hours0.6 ± 1.73.8 ± 2.2
2 hours0.5 ± 1.74.1 ± 2.1
4 hours0.8 ± 2.24.3 ± 2.2
6 hours2.5 ± 2.24.0 ± 1.9
8 hours1.8 ± 2.13.5 ± 2.2
10 hours1.3 ± 2.03.0 ± 2.2
12 hours2.0 ± 2.62.7 ± 2.1
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.22 · 95% CI 0.69 to 1.74
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 2.43 · 95% CI 1.77 to 3.09
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 3.22 · 95% CI 2.49 to 3.95
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 3.70 · 95% CI 2.98 to 4.42
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 3.50 · 95% CI 2.67 to 4.33
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.53 · 95% CI 0.79 to 2.27
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.67 · 95% CI 0.87 to 2.48
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 1.76 · 95% CI 0.97 to 2.54
  • Placebo vs Ibuprofen · ANOVA · p = 0.056 (p-Values from ANOVA model with treatment, baseline PSR, and gender terms.) · Least squares means: 0.78 · 95% CI -0.02 to 1.58
SecondaryTime-weighted Sum of Pain Relief Scores (TOTPAR)

TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).

Time frame:
0-12 hours, 8-12 hours
Reported as:
Mean · units on a scale
Time-weighted Sum of Pain Relief Scores (TOTPAR)
units on a scalePlaceboIbuprofen
TOTPAR 0 to 1214.1 ± 11.228.7 ± 12.3
TOTPAR 8 to 127.8 ± 7.212.9 ± 7.4
Statistical analysis
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 14.82 · 95% CI 10.38 to 19.25
  • Placebo vs Ibuprofen · ANOVA · p = <0.001 (p-Value from ANOVA model with treatment, baseline pain severity, and gender terms.) · Least squares means: 5.27 · 95% CI 2.57 to 7.98
SecondaryNumber of Doses of Rescue Medication Used
Time frame:
0-12, 12-24, 24-36, 36-48, 0-48 hours
Reported as:
Mean · doses
Number of Doses of Rescue Medication Used
dosesPlaceboIbuprofen
First dosing interval (0-12 hours)1.3 ± 1.00.4 ± 0.6
Second dosing interval (12-24 hours)0.4 ± 0.60.1 ± 0.2
Third dosing interval (24-36 hours)0.5 ± 0.90.1 ± 0.5
Fourth dosing interval (36-48 hours)0.3 ± 0.70.1 ± 0.3
Overall during the study (0-48 hours)2.5 ± 2.60.6 ± 1.5
Statistical analysis
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.) · Cmh-adjusted proportion: -0.73 · 95% CI -0.91 to -0.55
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (Treatment difference (ibuprofen minus placebo) and corresponding 95% CI were calculated based on CMH-adjusted proportions and corresponding standard errors.) · Cmh-adjusted proportions: -0.72 · 95% CI -1.05 to -0.40
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = 0.002 (p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.) · Cmh-adjusted proportions: -0.48 · 95% CI -0.90 to -0.06
  • Placebo · Cochran-Mantel-Haenszel · p = 0.021 (p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.) · Cmh-adjusted proportion: -0.68 · 95% CI -1.02 to -0.35
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.) · Cmh-adjusted proportion: -0.70 · 95% CI -0.89 to -0.51
SecondaryTime to Confirmed First Perceptible Relief

The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.

Time frame:
Baseline to 12 hours
Reported as:
Median · minutes
Time to Confirmed First Perceptible Relief
minutesPlaceboIbuprofen
Time to Confirmed First Perceptible ReliefNA (NA to NA)25.0 (20.1 to 28.5)
SecondaryTime to Meaningful Relief

Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.

Time frame:
Baseline to 12 hours
Reported as:
Median · minutes
Time to Meaningful Relief
minutesPlaceboIbuprofen
Time to Meaningful ReliefNA (NA to NA)54.2 (46.5 to 79.6)
SecondaryParticipant Global Evaluation Score

Participants responded, on a 6-point categorical scale, to the following question: "How would you rate this medication as a pain-reliever?" Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.

Time frame:
24 and 48 hours
Reported as:
Mean · units on a scale
Participant Global Evaluation Score
units on a scalePlaceboIbuprofen
24 hours1.2 ± 1.43.5 ± 1.2
48 hours1.7 ± 1.53.7 ± 1.0
Statistical analysis
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 (p-Value from the CMH test with modified ridit scores, controlling for baseline PSR score and gender.) · Gamma statistic: 0.85 · 95% CI 0.74 to 0.95
  • Placebo vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.001 · Gamma statistic: 0.79 · 95% CI 0.66 to 0.92p-Value from the CMH test with modified ridit scores, controlling for baseline PSR score and gender.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/52 (0%)23/52 (44.2%)
Ibuprofen—0/54 (0%)8/54 (14.8%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboIbuprofen
NauseaGastrointestinal disorders10/521/54
HeadacheNervous system disorders9/524/54
VomitingGastrointestinal disorders6/520/54
Feeling hotGeneral disorders2/520/54
PruritusSkin and subcutaneous tissue disorders0/522/54
Ear painEar and labyrinth disorders1/520/54
ChillsGeneral disorders1/520/54
FlushingGeneral disorders1/520/54
Blood pressure increasedInvestigations1/520/54
DizzinessNervous system disorders1/520/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboIbuprofenTotal
Mean21.1 ± 3.321.3 ± 3.621.2 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofenTotal
Female333669
Male191837
Pain Severity
Pain Severity(participants)PlaceboIbuprofenTotal
Moderate373976
Severe151530
Pain Intensity
Pain Intensity(millimeter)PlaceboIbuprofenTotal
Mean73.8 ± 12.2575.7 ± 12.1874.8 ± 12.20
08

Study locations

2 sites
  • Central Texas Oral Surgery Associates
    Austin, Texas 78705, United States
  • Premier Research
    Austin, Texas 78705, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Mar 2011, 4 months.

Results were first posted in Aug 2018, 7 years 4 months after primary completion. A results delay was requested in Apr 2012.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2010
First posted
Dec 24, 2010
StartActual
Nov 22, 2010
Primary completionActual
Mar 31, 2011
CompletionActual
Mar 31, 2011
Results delay requested
Apr 19, 2012
Results first posted
Aug 15, 2018
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01266161
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 24, 2010
Start date
Nov 22, 2010
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011
Results posted
Aug 15, 2018
Last update
Aug 15, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion